Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

929
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
929
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.6K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.6K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.7K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.7K
Esters to β-Ketoesters: Claisen Condensation Overview01:24

Esters to β-Ketoesters: Claisen Condensation Overview

4.2K
Regular Claisen condensation is a base-promoted reaction involving identical esters with two α hydrogens, condensing to produce β-ketoesters. It is a nucleophilic acyl substitution reaction wherein one of the ester molecules, upon deprotonation by the base, forms a nucleophilic enolate ion, while the other molecule serves as an electrophile.
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insulin resistance and type 2 diabetes as allostatic responses to chronic nutrient excess.

Cell metabolism·2026
Same author

Activation of the protective arm of renin-angiotensin system enhances mitochondrial turnover improving respiration and decreasing integrated stress response in a human Complex III deficiency model.

bioRxiv : the preprint server for biology·2026
Same author

Definition and diagnostic criteria of clinical obesity.

The lancet. Diabetes & endocrinology·2025
Same author

Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines.

BMC medicine·2024
Same author

Obesogens: a unifying theory for the global rise in obesity.

International journal of obesity (2005)·2024
Same author

Reactive oxygen species: role in obesity and mitochondrial energy efficiency.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2023

Related Experiment Video

Updated: Feb 4, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.4K

β-Cell Failure or β-Cell Abuse?

Karel Erion1, Barbara E Corkey2

  • 1Division of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.

Frontiers in Endocrinology
|October 2, 2018
PubMed
Summary

Type 2 Diabetes treatment dogma is questioned. High insulin levels may drive weight gain and insulin resistance, suggesting chronic beta-cell overstimulation, not just failure, underlies the condition.

Keywords:
beta-cellhyperinsuilnemiainsulin resistanceobesitytype 2 diabetes

More Related Videos

Author Spotlight: Assessment of Mitophagy Flux in Pancreatic β-Cells Using Effective and Robust Complementary Approaches
07:04

Author Spotlight: Assessment of Mitophagy Flux in Pancreatic β-Cells Using Effective and Robust Complementary Approaches

Published on: September 15, 2023

2.2K
A β-glucuronidase GUS Based Cell Death Assay
07:35

A β-glucuronidase GUS Based Cell Death Assay

Published on: May 6, 2011

28.7K

Related Experiment Videos

Last Updated: Feb 4, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.4K
Author Spotlight: Assessment of Mitophagy Flux in Pancreatic β-Cells Using Effective and Robust Complementary Approaches
07:04

Author Spotlight: Assessment of Mitophagy Flux in Pancreatic β-Cells Using Effective and Robust Complementary Approaches

Published on: September 15, 2023

2.2K
A β-glucuronidase GUS Based Cell Death Assay
07:35

A β-glucuronidase GUS Based Cell Death Assay

Published on: May 6, 2011

28.7K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Diabetes Research

Background:

  • Traditional Type 2 Diabetes (T2D) treatment focuses on insulin resistance driving beta-cell failure.
  • This dogma has not led to significant improvements in T2D outcomes.
  • Hyperlipidemia, insulin resistance, and hyperinsulinemia precede T2D diagnosis and are interconnected.

Purpose of the Study:

  • To challenge the established view of insulin resistance as the primary driver of T2D.
  • To explore the role of chronic hyperinsulinemia and beta-cell overstimulation in T2D pathogenesis.
  • To re-evaluate the definition of beta-cell dysfunction in T2D as potential 'abuse' rather than 'failure'.

Main Methods:

  • Review of existing literature and experimental data.
  • Analysis of the interplay between hyperlipidemia, insulin resistance, and hyperinsulinemia.
  • Investigation into non-glucose-stimulated insulin secretion by nutrients and toxins.

Main Results:

  • High circulating insulin levels are implicated in driving weight gain and insulin resistance.
  • Certain nutrients and environmental toxins can stimulate insulin secretion independently of glucose levels and insulin resistance.
  • Evidence suggests chronic beta-cell overstimulation may be a key factor in T2D.

Conclusions:

  • The prevailing model of T2D pathogenesis requires re-evaluation.
  • Chronic beta-cell overstimulation ('abuse') may be a more accurate description of dysfunction than simple 'failure'.
  • Understanding these mechanisms is crucial for developing effective T2D prevention and treatment strategies.